FDA Approves Biannual HIV Prevention Injection Based on University of Utah Research
TL;DR Summary
University of Utah biochemist Wesley Sundquist's research led to the development of lenacapavir, an HIV drug approved by the FDA that prevents transmission for six months and has the potential to significantly impact HIV prevention efforts worldwide.
- FDA approves HIV drug based on University of Utah biochemist's findings KSL News
- Regulators Approve a Twice-Yearly Shot to Prevent H.I.V. Infection The New York Times
- The decades-long journey to Gilead’s twice-a-year HIV prevention drug lenacapavir STAT
- FDA approves twice-a-year injection for HIV prevention CNN
- FDA approves powerful HIV prevention drug: What to know about Yeztugo NBC News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
94%
614 → 37 words
Want the full story? Read the original article
Read on KSL News